Olaparib, a poly(ADP-ribose) polymerase (PARP) enzyme inhibitor, in tablet form is indicated, among other things, for the maintenance treatment of adult patients with platinum-sensitive recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who respond (complete or partial response) to platinum-based chemotherapy. Its efficacy in this indication in terms of prolonging progression-free survival and overall survival was addressed by the phase III study presented below.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
